Pyxis Oncology (PYXS) Total Current Liabilities (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Total Current Liabilities data on file, last reported at $21.1 million in Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 19.52% year-over-year to $21.1 million in Q4 2025; TTM through Dec 2025 was $21.1 million, a 19.52% increase from a year earlier, with the FY2025 full-year figure at $21.1 million, up 19.52% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $21.1 million, up from $19.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for PYXS reached as high as $31.6 million in Q4 2022 and fell as low as $9.2 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $18.7 million across 5 years, with a median of $18.2 million in 2021.
• Across the five-year window, Total Current Liabilities surged 407.13% in 2021 and sank 39.54% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $18.7 million in 2021, then surged by 69.09% to $31.6 million in 2022, then declined by 18.57% to $25.8 million in 2023, then tumbled by 31.36% to $17.7 million in 2024, then gained by 19.52% to $21.1 million in 2025.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $21.1 million in Q4 2025, $19.4 million in Q3 2025, and $17.7 million in Q2 2025.